Previous 10 | Next 10 |
TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21 st Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Tuesday, April 12, 2022. Live audio of the even...
Heron has lost 60% of its value in less than a year, despite the company making some progress. Zynrelef's launch is slow but showing signs of improvement with some important inflection points. CINV franchise has also disappointed and HTX-019 in PONV is now the only likely growth d...
Pacira BioSciences (NASDAQ:PCRX) reported February preliminary net product sales for EXPAREL (bupivacaine liposome injectable suspension) of $41.7M. EXPAREL average daily sales for the month of February 2022 were 117% of February 2021. Net product sales for iovera of $0.9M for the month....
TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL ® (bupivacaine liposome...
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 10:15 AM ET on Wednesday, March 16, 2022 in Miami. Live audio of the event can...
John Paulson’s 13F portfolio value decreased from $3.51B to $3.24B this quarter. Paulson & Company increased Pacira Biosciences and SSR mining while reducing Brightsphere Investment Group and Thryv Holdings. The top three positions are at 49% of the portfolio. For...
Pacira BioSciences, Inc. (PCRX) Q4 2021 Earnings Conference Call February 24, 2022 8:30 a.m. ET Company Participants Susan Mesco - Investor Relations Dave Stack - Chairman and Chief Executive Officer Charlie Reinhart - Chief Financial Officer Roy Winston - Chief Medical Officer Conference Cal...
The following slide deck was published by Pacira BioSciences, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Pacira BioSciences, Inc. 2021 Q4 - Results - Earnings Call Presentation
Pacira BioSciences press release (NASDAQ:PCRX): Q4 Non-GAAP EPS of $0.97 beats by $0.14. Revenue of $159.19M (+21.5% Y/Y) beats by $1.77M. “The acquisition of Flexion Therapeutics combined with record EXPAREL sales resulted in a pivotal year for Pacira, allowing us to enter 2022 in the...
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patients have received EXPAREL since launch &...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...